Steven Sloan - Biomerica CFO Treasurer
| BMRA Stock | USD 0.56 0.07 11.11% |
Insider
Steven Sloan is CFO Treasurer of Biomerica
| Age | 54 |
| Phone | (949) 645-2111 |
| Web | https://www.biomerica.com |
Steven Sloan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Steven Sloan against Biomerica stock is an integral part of due diligence when investing in Biomerica. Steven Sloan insider activity provides valuable insight into whether Biomerica is net buyers or sellers over its current business cycle. Note, Biomerica insiders must abide by specific rules, including filing SEC forms every time they buy or sell Biomerica'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Steven Sloan over six months ago Acquisition by Steven Sloan of 25000 shares of Biomerica at 6.36 subject to Rule 16b-3 |
Biomerica Management Efficiency
The company has return on total asset (ROA) of (0.3854) % which means that it has lost $0.3854 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7648) %, meaning that it created substantial loss on money invested by shareholders. Biomerica's management efficiency ratios could be used to measure how well Biomerica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Tyla Bucher | Movano Inc | N/A | |
| Andre Marquette | Neuropace | N/A | |
| Rebecca Kuhn | Neuropace | 64 | |
| Sam Park | Sight Sciences | 63 | |
| Veronica Cai | Tivic Health Systems | 48 | |
| Richard Ginn | Tenon Medical | 59 | |
| Christopher Lesovitz | STRATA Skin Sciences | 41 | |
| John Esq | Ainos Inc | 57 | |
| Mark Saxton | Neuropace | 59 | |
| John Ordway | Sight Sciences | N/A | |
| Jennifer Ernst | Tivic Health Systems | 57 | |
| Michael Goodman | STRATA Skin Sciences | N/A | |
| Marilyn Elson | Nexalin Technology | 72 | |
| Blake Gurfein | Tivic Health Systems | 41 | |
| MBA BS | Sight Sciences | N/A | |
| Nikolai Kabelev | STRATA Skin Sciences | 48 | |
| Michael Favet | Neuropace | 54 | |
| Darrell Rigel | STRATA Skin Sciences | 73 | |
| Joel Bradus | Nexalin Technology | N/A | |
| Jeremy Hayden | Sight Sciences | 54 | |
| Jesse Selnick | Sight Sciences | N/A | |
Management Performance
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.39 |
Biomerica Leadership Team
Elected by the shareholders, the Biomerica's board of directors comprises two types of representatives: Biomerica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biomerica. The board's role is to monitor Biomerica's management team and ensure that shareholders' interests are well served. Biomerica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biomerica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Allen Barbieri, Independent Director | ||
| Zackary Irani, Chairman, CEO and Pres | ||
| Hans Boehringer, VP RD | ||
| Gary CPA, Principal CFO | ||
| Steven Sloan, CFO Treasurer | ||
| Lucy Liu, Director Operations | ||
| Robert Carlson, Chief Officer |
Biomerica Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biomerica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.39 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (0.76) % | ||||
| Current Valuation | 9.81 M | ||||
| Shares Outstanding | 16.82 M | ||||
| Shares Owned By Insiders | 7.21 % | ||||
| Shares Owned By Institutions | 13.01 % | ||||
| Number Of Shares Shorted | 275.49 K | ||||
| Price To Earning | (25.64) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biomerica offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomerica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomerica Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomerica Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomerica. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Medical Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomerica. If investors know Biomerica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomerica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biomerica is measured differently than its book value, which is the value of Biomerica that is recorded on the company's balance sheet. Investors also form their own opinion of Biomerica's value that differs from its market value or its book value, called intrinsic value, which is Biomerica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomerica's market value can be influenced by many factors that don't directly affect Biomerica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomerica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomerica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomerica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.